mediskin intensive moisture calming mask pack- glycerin liquid
kocorium - glycerin (unii: pdc6a3c0ox) (glycerin - unii:pdc6a3c0ox) - moisture and calming 1. cleanse and dry face thoroughly. 2. open pouch, unfold mask and apply to face. 3. leave it for 10 - 20 minutes, remove the mask and tap slightly until essence absorbed.
mediskin intensive brightening mask pack- glycerin liquid
kocorium - glycerin (unii: pdc6a3c0ox) (glycerin - unii:pdc6a3c0ox) - brightening and moisturizing 1. cleanse and dry face thoroughly. 2. open pouch, unfold mask and apply to face. 3. leave it for 10 - 20 minutes, remove the mask and tap slightly until essence absorbed.
mediskin intensive firming mask pack- glycerin liquid
kocorium - glycerin (unii: pdc6a3c0ox) (glycerin - unii:pdc6a3c0ox) - firming and moisturizing 1. cleanse and dry face thoroughly. 2. open pouch, unfold mask and apply to face. 3. leave it for 10 - 20 minutes, remove the mask and tap slightly until essence absorbed.
anchor mediskin liquid bandage
polyurethane, ethyl acetate,ethanol
anchor mediskin liquid bandage
polyurethane, ethyl acetate,ethanol
medisone cream 0.1% ww
world medicare supplies sdn bhd - betamethasone 17 valerate -
pecfent 100
medison pharma ltd - fentanyl as citrate - nasal spray, solution - fentanyl as citrate 1 mg / 1 ml - fentanyl - pecfent is indicated for the management of breakthrough pain (btp) in adults who are already receiving maintenance opioid therapy for chronic cancer pain. breakthrough pain is a transitory exacerbation of pain that occurs on a background of otherwise controlled persistent pain.patients receiving maintenance opioid therapy are those who are taking at least 60 mg of oral morphine daily, at least 25 micrograms of transdermal fentanyl per hour, at least 30 mg of oxycodone daily, at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid for a week or longer.
pecfent 400
medison pharma ltd - fentanyl as citrate - nasal spray, solution - fentanyl as citrate 4 mg / 1 ml - fentanyl - pecfent is indicated for the management of breakthrough pain (btp) in adults who are already receiving maintenance opioid therapy for chronic cancer pain. breakthrough pain is a transitory exacerbation of pain that occurs on a background of otherwise controlled persistent pain.patients receiving maintenance opioid therapy are those who are taking at least 60 mg of oral morphine daily, at least 25 micrograms of transdermal fentanyl per hour, at least 30 mg of oxycodone daily, at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid for a week or longer.
kuvan
medison pharma ltd - sapropterin dihydrochloride - tablets soluble - sapropterin dihydrochloride 100 mg - sapropterin - sapropterin - kuvan is indicated for the treatment of hyperphenylalaninaemia (hpa) in adults and paediatric patients of all ages with phenylketonuria (pku) who have been shown to be responsive to such treatment.kuvan is also indicated for the treatment of hyperphenylalaninaemia (hpa) in adults and paediatric patients of all ages with tetrahydrobiopterin (bh4) deficiency who have been shown to be responsive to such treatment.
oxaliplatin medison
medison pharma ltd - oxaliplatin 5 mg/ml - concentrate for solution for infusion - oxaliplatin - oxaliplatin in combination with 5- fluorouracil and folinic acid (fa), oxaliplatin is indicated for: - adjuvant treatment of stage iii ( duke's c) colon cancer after complete resection of primary tumour - the treatment of metastatic colorectal cancer.